BACKGROUND: Insulin resistance is associated with multiple risk factors for cardiovascular (CV) disease in the general population. Patients on peritoneal dialysis (PD) are more likely to develop insulin resistance. However, no evaluation of the impact of insulin resistance on CV disease morbidity or mortality in patients on PD has been performed. METHODS: Our prospective cohort study included all non-diabetic patients on PD at our center (n = 66). Insulin resistance was evaluated at baseline by the homeostasis model assessment method (HOMA-IR) using fasting glucose and insulin levels. The cohort was followed for up to 58 months (median: 41.3 months; interquartile range: 34.3 months). A multivariate Cox model was used to analyze the impact of insulin resistance on CV disease mortality. RESULTS: Fourteen CV events occurred in the higher HOMA-IR group [IR-H (HOMA-IR values in the range 2.85 - 19.5), n = 33], but only one event occurred in the lower HOMA-IR group (IR-L (HOMA-IR values in the range 0.83 - 2.71), n = 33) during the follow-up period. Level of HOMA-IR was a significant predictor of CV events [risk ratio: 17.7; 95% confidence interval (CI): 2.10 to 149.5; p = 0.008]. In the IR-H group, 10 patients died (8 CV events), but in the IR-L group, only 4 patients died (1 CV event). Patients in the IR-H group experienced significantly higher CV mortality (hazard ratio: 9.02; 95% CI: 1.13 to 72.2; p = 0.04). Even after adjustments for age, systolic blood pressure, body mass index, C-reactive protein, triglycerides, resistin, and leptin, HOMA-IR remained an independent predictor of CV mortality (hazard ratio: 14.8; 95% CI: 1.22 to 179.1; p = 0.03). CONCLUSIONS: Insulin resistance assessed using HOMA-IR was an independent predictor of CV morbidity and mortality in a cohort of nondiabetic patients on PD. Insulin resistance is a modifiable risk factor; the reduction of insulin resistance may reduce CV risk and improve survival in this group of patients.
BACKGROUND:Insulin resistance is associated with multiple risk factors for cardiovascular (CV) disease in the general population. Patients on peritoneal dialysis (PD) are more likely to develop insulin resistance. However, no evaluation of the impact of insulin resistance on CV disease morbidity or mortality in patients on PD has been performed. METHODS: Our prospective cohort study included all non-diabeticpatients on PD at our center (n = 66). Insulin resistance was evaluated at baseline by the homeostasis model assessment method (HOMA-IR) using fasting glucose and insulin levels. The cohort was followed for up to 58 months (median: 41.3 months; interquartile range: 34.3 months). A multivariate Cox model was used to analyze the impact of insulin resistance on CV disease mortality. RESULTS: Fourteen CV events occurred in the higher HOMA-IR group [IR-H (HOMA-IR values in the range 2.85 - 19.5), n = 33], but only one event occurred in the lower HOMA-IR group (IR-L (HOMA-IR values in the range 0.83 - 2.71), n = 33) during the follow-up period. Level of HOMA-IR was a significant predictor of CV events [risk ratio: 17.7; 95% confidence interval (CI): 2.10 to 149.5; p = 0.008]. In the IR-H group, 10 patients died (8 CV events), but in the IR-L group, only 4 patients died (1 CV event). Patients in the IR-H group experienced significantly higher CV mortality (hazard ratio: 9.02; 95% CI: 1.13 to 72.2; p = 0.04). Even after adjustments for age, systolic blood pressure, body mass index, C-reactive protein, triglycerides, resistin, and leptin, HOMA-IR remained an independent predictor of CV mortality (hazard ratio: 14.8; 95% CI: 1.22 to 179.1; p = 0.03). CONCLUSIONS:Insulin resistance assessed using HOMA-IR was an independent predictor of CV morbidity and mortality in a cohort of nondiabeticpatients on PD. Insulin resistance is a modifiable risk factor; the reduction of insulin resistance may reduce CV risk and improve survival in this group of patients.
Authors: M Emoto; Y Nishizawa; K Maekawa; Y Hiura; H Kanda; T Kawagishi; T Shoji; Y Okuno; H Morii Journal: Diabetes Care Date: 1999-05 Impact factor: 19.112
Authors: Michael G Shlipak; Linda F Fried; Mary Cushman; Teri A Manolio; Do Peterson; Catherine Stehman-Breen; Anthony Bleyer; Anne Newman; David Siscovick; Bruce Psaty Journal: JAMA Date: 2005-04-13 Impact factor: 56.272
Authors: Jonas Axelsson; Abdul Rashid Qureshi; Mohammed E Suliman; Hirokazu Honda; Roberto Pecoits-Filho; Olof Heimbürger; Bengt Lindholm; Tommy Cederholm; Peter Stenvinkel Journal: Am J Clin Nutr Date: 2004-11 Impact factor: 7.045
Authors: Bernard G Jaar; Josef Coresh; Laura C Plantinga; Nancy E Fink; Michael J Klag; Andrew S Levey; Nathan W Levin; John H Sadler; Alan Kliger; Neil R Powe Journal: Ann Intern Med Date: 2005-08-02 Impact factor: 25.391
Authors: J P Després; B Lamarche; P Mauriège; B Cantin; G R Dagenais; S Moorjani; P J Lupien Journal: N Engl J Med Date: 1996-04-11 Impact factor: 91.245
Authors: Elinor C Mannon; Christina L Sartain; Trevin C Wilkes; Jingping Sun; Aaron J Polichnowski; Paul M O'Connor Journal: Am J Physiol Renal Physiol Date: 2021-08-16
Authors: Kelli R King-Morris; Serpil Muge Deger; Adriana M Hung; Phyllis Ann Egbert; Charles D Ellis; Amy Graves; Ayumi Shintani; T Alp Ikizler Journal: Perit Dial Int Date: 2015-11-02 Impact factor: 1.756
Authors: Ana Paula Bernardo; Jose C Oliveira; Olivia Santos; Maria J Carvalho; Antonio Cabrita; Anabela Rodrigues Journal: Clin J Am Soc Nephrol Date: 2015-10-27 Impact factor: 8.237